v3.26.1
Stockholders’ Equity (Tables)
 3 Months Ended
Apr. 03, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Stock-Based Compensation
We allocated the stock-based compensation for our 2017 Plan and our 2000 Employee Stock Purchase Plan (as amended and restated, the Amended ESPP) as follows (in thousands):
Three Months Ended March 31,
20262025
Research and development$12,318 $9,522 
Selling, general and administrative16,732 16,408 
Total stock-based compensation$29,050 $25,930 
Stock-based compensation for each type of award under our 2017 Plan and Amended ESPP were as follows (in thousands):
Three Months Ended March 31,
20262025
Stock options$253 $1,060 
Restricted stock units27,059 23,102 
Performance stock units— 241 
Employee stock purchase plan
1,738 1,527 
Total stock-based compensation$29,050 $25,930 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $55.31 per share for the 2026 TSR-based RSUs:
2026 TSR-based RSUs
Fair value of Exelixis common stock on grant date
$44.28 
Expected volatility
35.5%
Risk-free interest rate
3.4%
Dividend yield
—%